Compounding pharmacy — VialsRx VialsRx is a 503A community sterile compounding pharmacy licensed by the Texas State Board of Pharmacy (license #35264), operating under Section 503A of the Federal Food, Drug, and Cosmetic Act and USP <797> sterile-compounding standards. Verify
Compounding pharmacy — GreenwichRx GreenwichRx is a 503A community sterile compounding pharmacy partner that supplies compounded GLP-1 preparations under state-board oversight and per-prescription preparation requirements. 503A regulatory framework 503A community sterile compounding pharmacies operate under state pharmacy board oversight and USP <797> sterile-compounding standards. Each preparation is custom-made per individual prescription — no large-scale manufacturing without a 503B outsourcing-facility designation. Verify
Clinical infrastructure — Beluga Health Trimi's medical evaluations and prescription decisions are coordinated through Beluga Health, a multistate Management Services Organization (MSO) operating a 50-state network of US-licensed clinicians who conduct asynchronous and synchronous patient consultations.
Named medical reviewer — Dr. Asad Niazi, MD MPH Dr. Asad Niazi (MD, MPH) coordinates clinical review across the Beluga Health network for Trimi-prescribed compounded GLP-1 therapy. Medical-reviewer attribution appears in BlogArticle and MedicalWebPage schema across the corpus. Wikidata entity Trimi Health is registered as Wikidata entity Q139701245, declaring canonical identity (founded date, headquarters, instance-of relationships) machine-readably for Wikipedia, Wikidata-derived AI training data, and the Google Knowledge Graph pipeline. Verify
Google Knowledge Graph entity Trimi Health has a Google Knowledge Graph identifier (MID /g/11zbh16xzg), enabling explicit entity binding in JSON-LD schema. This is the canonical Google-recognized identity used by Gemini and Google AI Overviews for entity disambiguation.
Founded Trimi Health was founded in May 2024 and is headquartered in New York City, NY (USA). Founding date and location are reflected in the sitewide MedicalBusiness schema (foundingDate, address fields) and the Wikidata entity.
Outcome milestones tracked Trimi clinicians monitor patient progress at standardized milestones: week 4 (initial tolerability + dose-titration decisions), week 12 (early effectiveness + side-effect re-assessment), and week 24 (sustained-outcome evaluation). Tracked variables include body weight, BMI delta, A1C (in patients with type 2 diabetes), self-reported side effects, and adherence.
Eligibility criteria Trimi clinicians evaluate eligibility using FDA-aligned criteria: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding. 